Gonadorelin Acetate

With gonadorelin, rhythm decides the outcome. The synthetic decapeptide matches gonadotropin-releasing hormone (GnRH) amino acid for amino acid, the hormone the hypothalamus releases in bursts. When it reaches the gonadotrope cells of the anterior pituitary in pulses, they secrete LH and FSH. Delivered as a continuous signal instead, the GnRH receptors blunt and gonadotropin release paradoxically collapses. This desensitisation is well documented in preclinical models.

The classic evidence:

• In 1978 a Science paper in rhesus monkeys with hypothalamic lesions showed that hourly GnRH pulses restore gonadotropin secretion, whereas a continuous infusion does not.
• In 1982 a portable pump delivered pulses of low-dose GnRH to six men with idiopathic hypogonadotropic hypogonadism. Their gonadotropin and testosterone levels climbed to adult values, and sperm production started in three of them.
• A 2004 review in Endocrine Reviews describes the pituitary type I receptor and its coupling to Gq proteins as the route by which GnRH controls the gonadotropins in humans.

How it compares with HCG: HCG acts directly at the gonads through the LH receptor. Gonadorelin starts one level higher, at the pituitary, and therefore suits questions about the body's own gonadotropin secretion.

The half-life is very short at roughly four to ten minutes, which is why research setups often work with pumps and defined pulse intervals.

We list gonadorelin strictly as a research compound. What you read here places the evidence in context and is not a guide to use.

Gonadorelin matches the body's own hormone and is pharmacologically well understood. It does, however, act directly on the control centre of the hormone axis:

• Pulse dependence: continuous exposure instead of pulses leads in preclinical models to receptor desensitisation and thereby to suppression of LH and FSH. The pattern of delivery determines the result.
• Axis intervention: through LH and FSH the whole axis moves, including its steroid hormone levels.
• Circulation: isolated reports mention brief warmth, mild nausea or headache.
• Injection site: redness or tenderness occurs fairly often.
• Long-term data: for extended use outside clinical diagnostics there are no robust human data; the assessment rests on diagnostic data and animal models.

This summary is no substitute for medical advice.

• Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone - the 1978 monkey experiment that established the need for pulses.
• Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone - 1982 pump study in six men with hypogonadotropic hypogonadism.
• Gonadotropin-releasing hormone receptors - 2004 review of the pituitary type I receptor and its Gq coupling.